Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Anne Prener, M.D., Ph.D. joins Keros’s Board July 1, 2026, as a Class III director through the 2029 annual meeting.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Anne Prener, M.D., Ph.D. joins Keros’s Board July 1, 2026, as a Class III director through the 2029 annual meeting
- No committee assignment, related-party transactions, or appointment arrangements disclosed
- Initial equity package totals $300,000 fair value: $150,000 option and $150,000 RSUs
- Initial awards vest quarterly over three years and accelerate fully upon a change in control
- Ongoing compensation includes $150,000 annual equity awards and $41,500 cash retainer
Item 7.01 · Regulation FD Disclosure
- Dr. Prener appointed to Keros Therapeutics’ Board of Directors
- Board composition change may influence governance, oversight, and strategic direction
- Press release issued June 25, 2026; appointment details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Anne Prener, M.D., Ph.D. appointed independent director effective July 1, 2026
- Adds clinical-development and biopharmaceutical executive experience relevant to Keros’ pipeline execution
- Board expertise supports development of rinvatercept and elritercept across muscular, hematologic, and neurological indications
- Appointment does not change near-term clinical, regulatory, or funding risks facing this clinical-stage company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.